Avacta Life Sciences (Avacta Group plc) presented preclinical data on AVA-6103, a second-generation Precision peptide-drug conjugate, being developed for the potential treatment of cancer. AVA-6103 was developed using the company’s proprietary Precision technology incorporating a dipeptide specifically cleaved by fibroblast activation protein α (FAPα) leading to tumor-specific delivery of exatecan directly into the tumor cells.
Extending its cash runway into 2026, Sana Biotechnology Inc. is prioritizing certain autoimmune assets and punting an oncology program and a central nervous system diseases program to a potential licensing partner or spinout company.
Researchers from Liaoning Jinqiu Hospital and affiliated organizations explored potential new genetic targets in heart failure and breast cancer through combining genetic inference and single-cell expression analysis. Genome-wide association study (GWAS) identified multiple genetic variants that were causally related in heart failure and breast cancer.
While the size of the market is enormous, drug development and treatments for women’s health care still lag behind what is offered for men. There has been a renaissance in the past few years, however, led by investors and companies that have wrestled with determining exactly what encompasses women’s health and how to meet its challenges.
Cyrus Therapeutics Inc. has designed molecular glue degraders comprising a cereblon (CRBN)-binding moiety acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers potentially useful for the treatment of cancer.
Nuclear medicine combines structural and functional imaging, thus detecting lesions earlier than traditional methodologies. CD147 is a transmembrane glycoprotein that is expressed at very low levels in normal tissues, but significantly overexpressed in tumoral tissues, and is tied to clinical outcome and immune infiltration in cancer.
Researchers from Vrise Therapeutics Inc. and Vegen Therapeutics Pvt Ltd. presented preclinical data for VRTX-531, an allosteric inhibitor of ubiquitin carboxyl-terminal hydrolase 1 (USP1), being developed for the treatment of cancer.
Pancreatic ductal adenocarcinoma (PDAC) has a low 5-year survival rate of <12%. Even though KRAS is mutated in about 88% of PDACs, the KRAS G12C mutation is rare, limiting the use of KRAS G12C inhibitors. Hence, there is a need for pan-RAS inhibitors to cover the broad RAS mutation spectrum in PDAC.
Nectin-4 is a cell-adhesion molecule overexpressed in several tumor types, including breast, ovarian, lung, colorectal, pancreatic and urothelial cancer. Enfortumab vedotin (EV), an anti-Nectin-4 antibody-drug conjugate (ADC) has shown a good objective response rate in pretreated patients with advanced urothelial carcinoma. However, this effect has been linked to on-target skin toxicity.
RSS
